GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Minority Interest

EGEIRO Pharma (XPAR:ALVET) Minority Interest : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EGEIRO Pharma Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

EGEIRO Pharma's minority interest for the quarter that ended in Dec. 2023 was €0.00 Mil.


EGEIRO Pharma Minority Interest Historical Data

The historical data trend for EGEIRO Pharma's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EGEIRO Pharma Minority Interest Chart

EGEIRO Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Minority Interest
- - - - -

EGEIRO Pharma Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EGEIRO Pharma Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


EGEIRO Pharma Business Description

Traded in Other Exchanges
N/A
Address
Avenue Jean Mermoz 32/1, Gosselies, BEL, 6041
EGEIRO Pharma is a biopharmaceutical company. The company is focused on the clinical development of drugs for Idiopathic Pulmonary Fibrosis, a chronic, devastating, and fatal disease characterized by the deterioration of lung function.

EGEIRO Pharma Headlines

No Headlines